Britain and America have hammered out a major trade agreement that will guarantee no levies on British medicine exports going into the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to increase expenditure on drugs through the NHS. This pledge guarantees that import taxes on these vital products will be held at zero for a timeframe of three years.
This development follows previous warnings to significantly raise duties on patented pharmaceutical products, with increases discussed up to 100%.
"This agreement with the UK bolsters the global environment for new treatments and establishes much-needed balance to U.S.–U.K. medicine commerce," an announcement declared.
Economic Significance
Pharmaceuticals represent one of the Britain's biggest exports to the United States, which is by far the primary destination for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months prior to last September, the UK sold pharmaceutical products valued at billions to the US. This amount represented nearly one-fifth of all goods exports in that period.
"This deal secures jobs, boosts investment and paves the way for the UK to become a global hub for medical research," a government official stated.
Detailed UK Commitments
The pact involves several specific commitments from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to double total NHS spending on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to stay within budget will be limited at 15%. Previously, refunds topped twenty percent.
Recent Tensions
The pact takes place against a ongoing row between the sector and the ministers over medicine costs and approval rates.
These tensions were heightened by arguments that US customers were paying a premium for the same drugs than patients in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been halted or scrapped, while substantial funding commitments have been directed toward US facilities.
The Science Minister acknowledged that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the past decade.
